Acute kidney injury in liver cirrhosis: a global challenge.

Lancet Gastroenterol Hepatol

Department of Intensive Care, King's College London, Guy's & St Thomas' Hospital, London SE1 7EH, UK. Electronic address:

Published: March 2025

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(25)00044-5DOI Listing

Publication Analysis

Top Keywords

acute kidney
4
kidney injury
4
injury liver
4
liver cirrhosis
4
cirrhosis global
4
global challenge
4
acute
1
injury
1
liver
1
cirrhosis
1

Similar Publications

Background: The perioperative management of patients undergoing cardiac surgery is highly complex and involves numerous factors. There is a strong association between cardiac surgery and perioperative complications. The Brazilian Surgical Identification Study (BraSIS 2) aims to assess the incidence of death and early postoperative complications, identify potential risk factors, and examine both the demographic characteristics of patients and the epidemiology of cardiovascular procedures.

View Article and Find Full Text PDF

Continuous Kidney Replacement Therapies: Core Curriculum 2025.

Am J Kidney Dis

March 2025

Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Electronic address:

Critically ill patients that require kidney replacement therapy (KRT) are among the most ill and complex patients routinely encountered in the intensive care unit (ICU). Continuous KRT (CKRT) is used across many ICUs as the therapy of choice for hemodynamically unstable patients with kidney failure. Though existing trials have not shown superior survival or kidney recovery with CKRT relative to intermittent KRT, CKRT has largely become the standard of care in developed nations for the treatment of acute kidney injury (AKI) in patients with shock, acute brain injury, acute liver failure, and other forms of critical illness.

View Article and Find Full Text PDF

Risk of Serious Bacterial and Non-Bacterial Infections in People With MASLD.

Liver Int

April 2025

Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease globally. MASLD is a multisystem disease where metabolic dysfunction plays a key role in the development of MASLD and its most relevant liver-related morbidities and extrahepatic complications, such as cardiovascular disease, chronic kidney disease and certain types of extrahepatic cancers. Among the least examined MASLD-related extrahepatic complications, an ever-increasing number of observational studies have reported a positive association between MASLD and the risk of serious bacterial infections (SBI) requiring hospital admission.

View Article and Find Full Text PDF

Pharmacokinetics of Ampicillin-Sulbactam in Azotemic and Non-Azotemic Dogs.

J Vet Pharmacol Ther

March 2025

Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Science, Colorado State University, Fort Collins, Colorado, USA.

Previous research has shown that azotemic dogs have a lower clearance and higher drug plasma concentrations of ampicillin compared to healthy dogs. The objective of this study was to determine the pharmacokinetics of ampicillin-sulbactam after multiple intravenous doses in hospitalized azotemic and non-azotemic dogs. This prospective study included 29 client-owned dogs; 19 azotemic and 10 non-azotemic.

View Article and Find Full Text PDF

Mixed presentation of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) has been reported in up to 27% of hyperglycemic emergencies. This 15-year retrospective chart review describes clinical features, risk factors, and outcomes among children presenting with hyperglycemic emergencies at our center. Out of 322 patients, 92% were Afro-Caribbean or Black with a mean age of 13.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!